Abstract 124P
Background
Personalized cancer vaccines, targeting patients' tumor mutations, have significantly advanced cancer treatment. However, the use of neoantigens is restricted to tumors with sufficiently high mutational burden, limiting their use to selected cancer indications. The discovery of endogenous retroviruses (ERV) as relevant immunologic features contained in the dark genome and the research demonstrating their dynamic role in cancer development and progression provide potential prospects for therapeutic use. Evaxion Biotech’s core technology, AI-Immunology™ allows for identification and selection of ERVs as a new antigen source for designing personalized and precision therapeutic cancer vaccines. In the presented work we explore the efficacy of AI-Immunology™ identified ERVs as alternative antigens for cancer vaccines in preclinical mouse and human cell models. The basis of the tested vaccine designs are shared ERV antigenic hotspots, amino acid sequences containing one or more HLA allele ligands, targeting a broad population.
Methods
Mouse tumor studies were performed to validate AI-Immunology™ predicted murine ERV vaccine designs. For ERV antigen identification, RNA-sequencing data from different mouse tumor cell lines were used. The AI-Immunology™ selected antigens were encoded into plasmid DNA and mice were immunized intramuscularly with the plasmid DNA vaccine. The efficacy of the selected murine ERV antigens was evaluated based on the induction of functional antigen-specific T cells and ability to inhibit tumor growth. Furthermore, the ability of predicted human ERV antigens to induce an antigen-specific T-cell response was tested by in vitro stimulation of human PBMCs with ERV antigen peptides and measuring T-cell activation using ELISpot analysis.
Results
Immune analysis of the in vivo and in vitro studies demonstrate that the selected murine and human ERV antigenic hotspots induce significant antigen-specific T-cell responses in mice and human PBMCs. Murine ERV hotspots lead also to tumor growth inhibition in mice.
Conclusions
The obtained results prove that the AI-Immunology™ platform can identify functional and potent ERV antigenic hotspots. This warrants for further development towards clinical application.
Legal entity responsible for the study
Evaxion Biotech A/S.
Funding
Evaxion Biotech A/S.
Disclosure
D. Kleine-Kohlbrecher, S. Vester Kofoed, J. Kringelum, B. Rønø: Financial Interests, Personal, Full or part-time Employment: Evaxion Biotech; Financial Interests, Personal, Stocks/Shares: Evaxion Biotech. R. O. Andersen: Financial Interests, Personal, Full or part-time Employment: Evaxion Biotech A/S. M. B. Calvo, S. Friis, R. Villebro, M. S. Klausen, S.F. Thorsen: Financial Interests, Personal, Full or part-time Employment: Evaxion Biotech A/S; Financial Interests, Personal, Stocks/Shares: Evaxion Biotech A/S.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract